p. In a drug interaction study in healthy subjects (n = 10), the venetoclax Cmax and AUC values were decreased by 42% and 71%, respectively, following the co-administration of strong CYP3A4 inducer for 13 days. In another drug interaction study (n = 11), the venetoclax Cmax and AUC values were increased by 106% and 78%, respectively, when a single dose of a P-gp inhibitor was co-administered in healthy subjects.
Erythromycin: Avoid the concomitant use of venetoclax and erythromycin; venetoclax is a substrate of CYP3A4 and P-glycoprotein (P-gp) and erythromycin is a CYP3A4 (moderate) and P-gp inhibitor. Consider alternative agents. If concomitant use of these drugs is required, reduce the venetoclax dosage by at least 50% (maximum dose of 200 mg/day). If erythromycin is discontinued, wait 2 to 3 days and then resume the recommended venetoclax dosage (or prior dosage if less). Monitor patients for signs and symptoms of venetoclax toxicity such as hematologic toxicity, GI toxicity, and tumor lysis syndrome. In a drug interaction study (n = 11), the venetoclax Cmax and AUC values were increased by 106% and 78%, respectively, when a P-gp inhibitor was co-administered in healthy subjects.
Erythromycin; Sulfisoxazole: Avoid the concomitant use of venetoclax and erythromycin; venetoclax is a substrate of CYP3A4 and P-glycoprotein (P-gp) and erythromycin is a CYP3A4 (moderate) and P-gp inhibitor. Consider alternative agents. If concomitant use of these drugs is required, reduce the venetoclax dosage by at least 50% (maximum dose of 200 mg/day). If erythromycin is discontinued, wait 2 to 3 days and then resume the recommended venetoclax dosage (or prior dosage if less). Monitor patients for signs and symptoms of venetoclax toxicity such as hematologic toxicity, GI toxicity, and tumor lysis syndrome. In a drug interaction study (n = 11), the venetoclax Cmax and AUC values were increased by 106% and 78%, respectively, when a P-gp inhibitor was co-administered in healthy subjects.
Eslicarbazepine: Avoid the concomitant use of venetoclax and eslicarbazepine; venetoclax levels may be decreased and its efficacy reduced. Venetoclax is a CYP3A4 substrate and eslicarbazepine is a moderate CYP3A4 inducer. Consider alternative agents. In a drug interaction study (n = 11), the venetoclax Cmax and AUC values were decreased by 42% and 71%, respectively, following the co-administration of multiple doses of a strong CYP3A4 inducer. Use of venetoclax with a moderate CYP3A4 inducer has not been eva luated.
Etoposide, VP-16: Avoid the concomitant use of venetoclax and oral etoposide, VP-16 as etoposide levels may be increased. If concomitant use of these drugs is required, administer etoposide at least 6 hours before venetoclax. Monitor patients for signs and symptoms of etoposide toxicity. Venetoclax is an inhibitor of P-glycoprotein (P-gp) and etoposide is a P-gp substrate with a narrow therapeutic index; these agents may interact in the gastrointestinal tract.
Etravirine: Avoid the concomitant use of venetoclax and etravirine; venetoclax levels may be altered. Consider alternative agents. Venetoclax is a substrate of CYP3A4 and P-glycoprotein (P-gp) and etravirine is a moderate inducer of CYP3A4 and an inhibitor of P-gp. In a drug interaction study in healthy subjects (n = 10), the venetoclax Cmax and AUC values were decreased by 42% and 71%, respectively, following the co-administration of multiple doses of a strong CYP3A4 inducer. Use of venetoclax with a moderate CYP3A4 inducer has not been e |
